European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital AmaurosisGlobeNewsWire • 02/23/21
Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common StockGlobeNewsWire • 02/11/21
4 Penny Stocks on the Run: Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Technologies (OTC US: ALPP), Enzolytics (OTC US: ENZC), and Ocugen (NASDAQ: OCGN)OTC PR Wire • 02/10/21